Key result
Multiple cardiac autoantibodies linked to ~16-fold higher cardiovascular risk in type 1 diabetes.
Why the study?
Poor glycemic control increases cardiovascular disease risk in T1DM, but mechanisms specific to T1DM, such as whether chronic hyperglycemia-induced cardiac autoimmunity contributes to complications, remain unknown.
Does positivity for ≥2 cardiac autoantibodies increase the risk of cardiovascular events in patients with type 1 diabetes mellitus?
Cohort (n=166)
Yes
Does positivity for ≥2 cardiac autoantibodies increase the risk of cardiovascular events in patients with type 1 diabetes mellitus?
Cardiac autoantibody positivity may serve as an early biomarker for long-term cardiovascular risk in patients with type 1 diabetes mellitus.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Her group has also shown that poor glycemic control in patients with type 1 diabetes — but not in those with type 2 diabetes — was associated with cardiac autoimmunity. An unexpected finding was the similar cardiac autoantibody levels in the patients with type 1 diabetes, who were young adult and without diabetes complications, and a heart failure cohort with Chagas' cardiomyopathy, which is thought to be caused by chronic inflammation of the heart muscle ('myocarditis'), raising the possibility of a subclinical autoimmune-associated myocardial dysfunction in type 1 diabetes”
“Heart failure in particular has recently been recognized as an important complication of type 1 with national register-based studies showing tenfold increased risk of heart failure in individuals with poor glycemic control. In addition, there's a higher case fatality rate in type 1 than type 2 diabetes, which suggests different mechanisms for heart failure might be involved in type 1 diabetes.”
May flag long-term cardiovascular risk in type 1 diabetes; hypothesis-generating and requires prospective validation before clinical use.
Background: Poor glycemic control is associated with increased risk of cardiovascular disease (CVD) in type 1 diabetes mellitus (T1DM); however, little is known about mechanisms specific to T1DM. In T1DM, myocardial injury can induce persistent cardiac autoimmunity. Chronic hyperglycemia causes myocardial injury, raising the possibility that hyperglycemia-induced cardiac autoimmunity could contribute to long-term CVD complications in T1DM. Methods: We measured the prevalence and profiles of cardiac autoantibodies (AAbs) in longitudinal samples from the DCCT (Diabetes Control and Complications Trial) in participants with mean hemoglobin A 1c (HbA 1c ) ≥9.0% (n=83) and ≤7.0% (n=83) during DCCT. We assessed subsequent coronary artery calcification (measured once during years 7–9 in the post-DCCT EDIC [Epidemiology of Diabetes Interventions and Complications] observational study), high-sensitivity C-reactive protein (measured during EDIC years 4–6), and CVD events (defined as nonfatal myocardial infarction, stroke, death resulting from CVD, heart failure, or coronary artery bypass graft) over a 26-year median follow-up. Cardiac AAbs were also measured in matched patients with type 2 diabetes mellitus with HbA 1c ≥9.0% (n=70) and ≤7.0% (n=140) and, as a control for cardiac autoimmunity, patients with Chagas cardiomyopathy (n=51). Results: Apart from HbA 1c levels, the DCCT groups shared similar CVD risk factors at the beginning and end of DCCT. The DCCT HbA 1c ≥9.0% group showed markedly higher cardiac AAb levels than the HbA 1c ≤7.0% group during DCCT, with a progressive increase and decrease in AAb levels over time in the 2 groups, respectively ( P <0.001). In the HbA 1c ≥9.0% group, 46%, 22%, and 11% tested positive for ≥1, ≥2, and ≥3 different cardiac AAb types, respectively, similar to patients with Chagas cardiomyopathy, compared with 2%, 1%, and 0% in the HbA 1c ≤7.0% group. Glycemic control was not associated with AAb prevalence in type 2 diabetes mellitus. Positivity for ≥2 AAbs during DCCT was associated with increased risk of CVD events (4 of 6; hazard ratio, 16.1; 95% CI, 3.0–88.2) and, in multivariable analyses, with detectable coronary artery calcification (13 of 31; odds ratio, 60.1; 95% CI, 8.4–410.0). Patients with ≥2 AAbs subsequently also showed elevated high-sensitivity C-reactive protein levels (6.0 mg/L versus 1.4 mg/L in patients with ≤1 AAbs; P =0.003). Conclusions: Poor glycemic control is associated with cardiac autoimmunity in T1DM. Furthermore, cardiac AAb positivity is associated with an increased risk of CVD decades later, suggesting a role for autoimmune mechanisms in the development of CVD in T1DM, possibly through inflammatory pathways.
No takes yet. Share an insight, caveat, or question.
Sousa et al. (2019) conducted a cohort in Type 1 Diabetes Mellitus (n=166). Positivity for ≥2 cardiac autoantibodies (AAbs) vs. Positivity for ≤1 cardiac AAb was evaluated on Cardiovascular events (composite of nonfatal myocardial infarction, stroke, cardiovascular death, heart failure, or coronary artery bypass grafting) (HR 16.1, 95% CI 3.0-88.2, p=0.001). Positivity for ≥2 cardiac autoantibodies was associated with a 16.1-fold increased risk of cardiovascular events over a 26-year median follow-up in patients with type 1 diabetes mellitus.
Synapse has enriched 10 related papers. Consider them for comparative context: